Keywords: imclone, mystry, bidder, eli, lilly, biotechnology, firm

Is ImClone's mystry bidder Eli Lilly?

Article | 06 October 2008

Print This

US biotechnology firm ImClone, now the subject of a hostile $62 a share bid from Bristol-Myers Squibb (Marketletters passim), has revealed ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in